Abstract:Aim: The current research aims to establish a stability-indicating analytical method (SIAM) for the quantification of evodiamine (EVO), characterization of its degradation impurity, and establishment of possible degradation pathways. Background: None of the degradation impurities of EVO is known and the mechanism of their formation has not been reported in any literature to date. Moreover, a SIAM for EVO is not available in any public domain. Objective: The objective of this study is to characterize the degradation impurity of EVO by LC-MS/MS, proposing its molecular structure, identifying possible degradation pathways of generation of its impurity, and establishing a SIAM. Method: To assist future product development, a degradation study of EVO was performed and an RP-HPLC-based SIAM was developed. The major degradation product was characterized by LC-Q-TOF-MS/MS. In addition, in silico toxicity prediction was performed using the ProTox-ІI toxicity predictor. Result: The method was found to be linear, accurate, precise, and robust over the range of 12.5 to 100 μg /mL of EVO. The method met all the acceptance criteria as specified in the ICH guideline. Only one degradation product (9% of the drug area) of EVO was generated in acidic hydrolytic conditions. The degradation product was found to be potentially inactive for hepatotoxicity and immunotoxicity, with a confidence score of more than 0.7 (70%). Moreover, the confidence score for carcinogenicity, mutagenicity, and cytotoxicity was less than 0.7, indicating it was moderately inactive for these toxicities. Conclusion: The molecule was found to be stable in the majority of the tested stress conditions. However, the degradation product generated in acidic hydrolytic stress was characterized using LC-Q-TOF-MS/MS, which was unknown to date. The novelty of this research can be justified by the unavailability of any SIAM of EVO and the absence of any report on its susceptibility to degradation in the presence of different potential stressors. Moreover, the potential toxicity of the molecule and its impurity was not known previously. The reported degradation impurity may be useful to set the quality control acceptance criteria for EVO. Additionally, pharmaceutical industries and research laboratories may use the developed method for the analysis of quality control and stability samples of EVO.

Identification, Isolation and Characterization of Degradation Products (DPs) in Osimertinib Mesylate (OSM) Tablets by UHPLC-IMS-QTOF-MS, and NMR: Evaluation of Genotoxicity for OSM and DPs

Insight into in silico prediction and chemical degradation study of osimertinib mesylate by LC-HRMS and NMR: Investigation of a typical case of alkaline pH-mediated oxidative degradation product

Validation of Reverse Phase High-performance Liquid Chromatography Analytical Method for Osimertinib Mesylate and its Degradation Products for Osimertinib Mesylate Tablets

Forced Degradation Products of Olmesartan Medoxomil and their In Vitro Genotoxicity Assessment by Comet Assay using HEK Cells

Unveiling Pretomanid profiling using LC–MS/MS: integrating in-silico toxicity assessment and molecular docking analysis

Green Analytical Approach for HPLC Method Development for Quantification of Sorafenib and Its Pharmacopeia Impurities: LC–MS/MS Characterization and Toxicity Prediction of Stress Degradation Products

Forced Degradation Study of an Anti‐Diabetic Drug Imeglimin: Impurity Profiling and Structure Elucidation Using LC‐Q‐ToF‐MS/MS and NMR

Characterization of degradation products of silodosin under stress conditions by liquid chromatography/Fourier transform mass spectrometry

Identification and characterization of forced degradation products of sertraline hydrochloride using UPLC, ultra-high-performance liquid Chromatography-Quadrupole-Time of flight mass spectrometry (UHPLC-Q-TOF/MS/MS) and NMR

Isolation and Characterization of Related Substances in Alogliptin Benzoate by LC-QTOF Mass Spectrometric Techniques.

A comprehensive study to identify and characterize major degradation products of Ivermectin drug substance including its degradation pathways using LC-HRMS and NMR

Identification and Structural Characterization of New Degradation Products in Moxidectin Stressed Samples by LC-HRMS and NMR

Implementation of green analytical principles to develop and validate the HPLC method for the separation and identification of degradation products of Panobinostat, and its characterization by using LC-QTOF-MS/MS and its in-silico toxicity prediction using ADMET software

Analysis of omarigliptin forced degradation products by ultra‐fast liquid chromatography, mass spectrometry, and in vitro toxicity assay

LC/QTOF/MS/MS characterization, molecular docking and in silico toxicity prediction studies on degradation products of anagliptin

Comprehensive chromatographic analysis of Belumosudil and its degradation products: Development, validation, and In silico toxicity assessment

Characterization of the major degradation products of the praziquantel API by mass spectrometry: Development and validation of a stability-indicating reversed phase UPLC method

Isolation and characterization of novel degradation products in Fenoverine by LC-QTOF-MS/MS, LC-MS n and 2D-NMR

Oxidative stress-induced degradation of Brinzolamide: Isolation and in-depth characterization of unique hydroxylamine and oxime degradation products

Stability Indicating Analytical method, Characterization of Degradation Impurity by UPLC-Q-TOF-MS/MS, and Establishment of Degradation Mechanism of Evodiamine